IRIX

Iridex CEO Interviewed by The Ophthalmologist

Medical laser company, Iridex (IRIX), CEO David Bruce is interviewed on the company’s proprietary laster treatments for glaucoma. Iridex is unique in having treatment options across the entire spectrum of glaucoma progression: MLT (MicroPulse Laser Trabeculoplasty) for early-stage glaucoma TLT (MicroPulse Transscleral Laser Therapy) for moderate-stage glaucoma TSCPC (Transscleral cyclophotocoagulation) using the G-Probe for late-stage […]

Read More »

IRIDEX Announces Strategic Collaboration

At the market close today, Iridex Corporation (IRIX), a provider of ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced a major deal with $1 billion plus Japanese eye care company, Topcon. Highlights of the new strategic relationship include: The transaction nets $19.5 million of cash to Iridex, providing multiyear funding […]

Read More »

Iridex Lights Up

After a tough 2020, IRIDEX Corporation (IRIX), a provider of ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, has been on fire. Since December 14, the stock has more than doubled from $1.64. Today alone, the stock has been up by as much as 35%+ including the after hours session. The […]

Read More »